Globus Medical (NYSE:GMED) CFO Kyle Kline Sells 3,594 Shares

Globus Medical, Inc. (NYSE:GMED) CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kyle Kline also recently made the following trade(s):

• On Monday, December 1st, Kyle Kline sold 18,542 shares of Globus Medical stock. The stock was sold at an average price of $90.00, for a total transaction of $1,668,780.00.

Globus Medical Trading Down 2.9%

Shares of GMED traded down $2.72 during trading hours on Monday, hitting $91.75. 1,990,840 shares of the stock traded hands, compared to its average volume of 2,293,094. The business has a fifty day moving average of $86.41 and a 200-day moving average of $68.25. The firm has a market capitalization of $12.28 billion, a PE ratio of 29.60, a price-to-earnings-growth ratio of 1.58 and a beta of 1.06. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. The firm had revenue of $769.05 million for the quarter, compared to analysts’ expectations of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the firm earned $0.83 earnings per share. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, equities research analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup reiterated a “market perform” rating on shares of Globus Medical in a research report on Thursday. Zacks Research downgraded shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Wall Street Zen upgraded shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up previously from $93.00) on shares of Globus Medical in a report on Tuesday, November 18th. Finally, Barclays upped their price objective on shares of Globus Medical from $106.00 to $114.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Eight analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $97.78.

Institutional Trading of Globus Medical

Institutional investors have recently modified their holdings of the company. Advisory Services Network LLC bought a new stake in Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC lifted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. acquired a new position in Globus Medical during the second quarter valued at approximately $28,000. First Horizon Corp acquired a new stake in shares of Globus Medical in the 3rd quarter valued at $31,000. Finally, Parallel Advisors LLC grew its position in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.